Sanofi and Teva Pioneer Next-Generation IBD Treatment with Promising TL1A Antibody Results
Collaboration:
Sanofi and Teva have entered into an exclusive collaboration to co-develop and co-commercialize Teva’s duvakitug (anti-TL1A) for treating ulcerative colitis (UC) and Crohn’s disease (CD), two types of IBD14.
Clinical Results:
The Phase 2b study of duvakitug showed significant clinical remission rates of 36.2% for low-dose patients and 47.8% for high-dose patients, outperforming the placebo3.
Investment:
Sanofi invested $1.5 billion, with Teva receiving an upfront payment of $500 million and potentially earning up to $1 billion in development milestones13.
Precision Medicine:
The anti-TL1A antibody may offer a precision medicine approach by identifying patients more likely to respond based on genetic polymorphisms2.
Therapeutic Potential:
TL1A inhibition has shown promise in modulating immune pathways crucial for IBD and intestinal fibrosis, expanding therapeutic options5.
Commercialization:
Teva will lead commercialization in Europe, Israel, and specified other countries, while Sanofi will lead in North America, Japan, and the rest of the world1.
Sources:
1. https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2024/Teva-and-Sanofi-Announce-Accelerated-Timeline-for-Anti-TL1A-Phase-2b-Program-in-Patients-with-Inflammatory-Bowel-Disease/default.aspx
2. https://gi.org/journals-publications/ebgi/kochar_dec2024/
3. https://finimize.com/content/teva-and-sanofi-team-up-for-promising-ibd-drug
4. https://www.sanofi.com/en/media-room/press-releases/2023/2023-10-04-05-00-00-2754288